209. Deputy David Cullinane asked the Minister for Health the current status of negotiations regarding pricing for reimbursement for skyclarys. [44200/26]
Parliamentary questions
Questions
TDs ask ministers questions to get answers on the record, most of them in writing. Here is every one asked in the 34th Dáil, by the department it went to and the subject heading it was filed under. How questions work
Browse the questions
Showing questions under the heading Medicinal Products.
1,228 questions match, newest first.
270. Deputy Conor Sheehan asked the Minister for Health the criteria used to determine eligibility for specific medications to treat Parkinson’s disease on the long-term illness scheme; the frequency with which the list is reviewed to include new medications; when the next review will take place; and if she will make a statement on the matter. [44516/26]
1969. Deputy Barry Ward asked the Minister for Health her views on if delays in the approval of skyclarys as a treatment for friedrich's ataxia aligns with the "equitable access" as outlined in the National Rare Disease Strategy 2025-2030; and if she will make a statement on the matter. [41993/26]
1973. Deputy Barry Ward asked the Minister for Health her views on whether the treatment for friedrich's ataxia falls under an 'unmet need' as set out in the National Rare Diseases Strategy 2025-2030; and if she will make a statement on the matter. [41997/26]
2009. Deputy Emer Currie asked the Minister for Health further to Parliamentary Question No. 1167 of 26 May 2026, to specifically provide the estimated cost to the State of introducing free MART inhalers for this age cohort; and if she will make a statement on the matter. [42332/26]
2049. Deputy Ken O'Flynn asked the Minister for Health whether the forthcoming national medicines disposal programme will include medicine-level cataloguing, reimbursement category tracking, estimated retail value assessment, or analysis of prescribing source; and if she will make a statement on the matter. [42486/26]
2050. Deputy Ken O'Flynn asked the Minister for Health whether her Department or HSE has conducted any international benchmarking regarding medicines waste reduction strategies in comparable EU jurisdictions; and if so, to provide details. [42487/26]
2051. Deputy Ken O'Flynn asked the Minister for Health whether any estimate exists of medicines dispensed under State-funded schemes but not consumed due to non-adherence, therapy change, duplication, early discontinuation, death, hospital admission, or over-prescribing; and if she will make a statement on the matter. [42488/26]
2052. Deputy Ken O'Flynn asked the Minister for Health whether the HSE intends to publish annual reports arising from the new national medicines disposal programme, including estimated financial value and environmental impact of returned medicines. [42489/26]
2089. Deputy Maeve O'Connell asked the Minister for Health for an update on the available services for the disposal of unused or expired medication. [42618/26]
2106. Deputy Paul Nicholas Gogarty asked the Minister for Health the basis on which the HPRA authorised three recent ALURES projects involving potential use of 1,172 dogs and 932 cats over 60 month periods; the scrutiny applied to the necessity, proportionality, and welfare implications of these numbers; the identity of the project holders, establishments, animal sources, and products involved; the number of animals …
2111. Deputy Conor D. McGuinness asked the Minister for Health if givinostat will be made available for children with duchenne muscular dystrophy; and if she will make a statement on the matter. [42731/26]
2113. Deputy Pádraig O'Sullivan asked the Minister for Health if considering a policy under the Health (Pricing and Supply of Medical Goods) Act 2013 to qualify parallel imported medicines for reimbursement in Ireland at the same reference price as equivalent medicines supplied through the distribution channels of their original manufacturers; and if she will make a statement on the matter. [42753/26]
2146. Deputy Erin McGreehan asked the Minister for Health the specific positions Ireland will advocate during negotiations on the EU pharma package regarding incentives for the development and commercialisation of orphan medicines and advanced therapy medicinal products; and if she will make a statement on the matter. [42963/26]
2147. Deputy Erin McGreehan asked the Minister for Health the engagement her Department has had with Irish-based advanced therapy and rare disease stakeholders regarding the proposed changes to regulatory data protection and market exclusivity provisions under the EU pharma package; the concerns identified through this engagement; and if she will make a statement on the matter. [42964/26]
2148. Deputy Erin McGreehan asked the Minister for Health the role Ireland intends to play during its EU presidency in shaping the implementation of the Critical Medicines Act with regard to securing the supply chains for orphan medicines, advanced therapies and biologic medicines; and if she will make a statement on the matter. [42966/26]
2149. Deputy Erin McGreehan asked the Minister for Health the discussions taking place at EU level regarding the inclusion of advanced therapy medicinal products and orphan drugs within strategic stockpiling, procurement or supply resilience mechanisms under the Critical Medicines Act; and if she will make a statement on the matter. [42968/26]
2150. Deputy Erin McGreehan asked the Minister for Health the discussions taking place at EU level, in the context of the EU pharma package and Ireland’s forthcoming EU presidency, regarding greater cooperation between member states on access, pricing, reimbursement and procurement pathways for orphan medicines and advanced therapy medicinal products; and if she will make a statement on the matter. [42969/26]
2232. Deputy Barry Ward asked the Minister for Health the position regarding the decision process behind the review by the HSE Drugs Group regarding the reimbursement of risdiplam for adults living with spinal muscular atrophy (SMA); and if she will make a statement on the matter. [43302/26]
2247. Deputy John Paul O'Shea asked the Minister for Health the criteria used by the HSE to approve cholesterol-lowering injections for patients who are unable to tolerate statins; whether the cost of such treatment is covered by the HSE where a patient is deemed clinically eligible; and if she will make a statement on the matter. [43355/26]
2255. Deputy Pádraig O'Sullivan asked the Minister for Health if she is aware that according to a survey published by an organisation (details supplied) in May 2026, only 27% of orphan medicines for rare diseases approved between 2021 and 2024 were available to patients in Ireland as of January 2026, compared to an EU average of 43%; the steps being taken to improve access to orphan medicines for patients with rare d…
2256. Deputy Pádraig O'Sullivan asked the Minister for Health if she is aware that according to a survey published by an organisation (details supplied) in May 2026, patients in Ireland wait on average approximately 801 days for access to orphan medicines for rare diseases, compared to an EU average of 614 days; the measures being taken to reduce this waiting time; and if she will make a statement on the matter. [434…
2257. Deputy Pádraig O'Sullivan asked the Minister for Health the specific provisions of the Framework Agreement on the Supply and Pricing of Medicines agreed in March 2026 that will address the finding in a survey (details supplied) that Ireland has an orphan medicine availability rate of 27% against an EU average of 43%; and if she will make a statement on the matter. [43429/26]
2265. Deputy Mairéad Farrell asked the Minister for Health the position in relation to the reimbursement of internationalised normalised ratio test strips and machines for persons who require long-term oral anticoagulant therapy with warfarin; and if she will make a statement on the matter. [43499/26]
2266. Deputy Pádraig O'Sullivan asked the Minister for Health the number of patients receiving standard oral nutritional supplements reimbursed under the community drug schemes, broken down by those receiving first-line products on List A and those receiving non first-line products on List B, in tabular form; and if she will make a statement on the matter. [43512/26]